Cannabis Science, Inc. (CBIS)

cannabis_print_logoCannabis Science, Inc. is a patient-oriented biotech company that specializes in cannabis formulation-based drug development and consulting. It is dedicated to meeting the needs of the community with products that are based on cannabinoid science. With the company’s unique understanding of metabolic processes, it aims to provide innovative treatment options for people whose medical needs were unmet.

As one of the longest standing companies in the cannabis industry, Cannabis Science continues to provide products that are medical cannabinoid formulations. The company is committed to providing those in need of new treatments for debilitating and life-threatening conditions with access to high-quality cannabinoid pharmaceuticals, and advocating their rights.

Cannabis Science works with drug development experts, as wells as clinical research and medical characteristic experts to develop, manufacture, and commercialize cannabinoid-based therapeutic approaches that can help treat many different types of critical ailments, including age-related medical conditions, neurobehavioral disorders, infections, and cancer. The company also works closely with regulatory agencies in their effort to alleviate suffering and to promote health of patients through cannabinoid science.

Cannabis Science, Inc. is a pioneering biotech company that creates medical cannabinoid formulations developed from cannabinoid compounds, which are derived from the cannabis plant. The material used by the company for clinical trials comes from GMP-compliant cultivation and production facilities. Its immediate focus is to develop treatment for different medical conditions, including certain types of cancer. The company continues to improve its standards to develop cutting edge treatments for cancer and other medical conditions.

Trading in the OTC under the symbol CBIS, Cannabis Science, Inc. is the first and only existing publicly traded biotech company on the market involved in formulations that are based on cannabinoid extracts. As the leader in the industry, the company consults and leads emerging businesses with a preferred business model that can mature into a key business model.


Yahoo! Finance: CBIS News

Latest Financial News for CBIS

Cannabis Science Propels Cancer Clinical Trials, Appoints Cellular Cancer Specialist Dr. Sulma Mohammed, Professor of Cancer Biology, Purdue University, to the Company’s Scientific Advisory Board

IRVINE, CA, June 03, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce the appointment of Dr. Sulma Mohammed, Professor of Cancer Biology at Purdue University, to the Company’s Scientific Advisory Board. Dr. Mohammed has extensive knowledge of molecular biology, cell biology, biochemistry, and microbiology, basic and applied medical sciences through her graduate programs at Cornell University and Purdue University, as well as experience in cancer research from the basic levels, to pre-clinical research in animal models, through to human clinical trials.

GHC Summit at Harvard Medical School Announces Cannabis Science as Industry Partner in the Launch of the International Phytomedicines Institute at Harvard Medical School

IRVINE, CA, May 31, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the research and development of cannabinoid-based medicines, is proud to announce it has been introduced as one of the key industry partners in the recently launched, ground-breaking International Phytomedicines Institute (IPI) at Harvard Medical School. The International Phytomedicines Institute (IPI), launched during this year’s Harvard GHC Summit, is a transformative initiative by the Global Health Catalyst designed to elevate phytomedicines in global health, accelerate clinical translation and commercialization of evidence-based plant medicines/healthcare products and provide a world class core facility for research, and consultation on medicinal plants.

What Kind Of Shareholders Own Cannabis One Holdings Inc. (CNSX:CBIS)?

The big shareholder groups in Cannabis One Holdings Inc. (CNSX:CBIS) have power over the company. Institutions often...

Cannabis Science Set to Participate in the Premier Event Focused on High-Impact Global Collaborations; The Global Health Catalyst Summit at Harvard Medical School Starts Today

IRVINE, CA, May 24, 2019 -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to.

Cannabis Science Announces NFL Greats Past and Present Set to Participate and Partner With the Global Health Catalyst Summit at Harvard Medical School on May 24-26, 2019

IRVINE, CA, May 23, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce the upcoming Global Health Catalyst (GHC) Summit at Harvard Medical School has been further enhanced with the announced participation of some of the greatest NFL Players of all time. The expectation by Summit organizers and participants is that this year’s event will be the biggest and most impactful GHC Summit to date. “For Cannabis Science, this is a dream come true!” stated Mr. Raymond C. Dabney, CBIS’ President, CEO, and Co-founder.